{
    "nctId": "NCT02838810",
    "officialTitle": "The Optimizing Treatment of PegIFN Alfa in HBeAg-negative Chronic Hepatitis B Patients With Low Level HBsAg",
    "inclusionCriteria": "1. CHB patients who had received single NAs for more than 12 months.\n2. Hepatitis B e antigen (HBeAg)-negative.\n3. Hepatitis B surface antigen (HBsAg) positive and \\<1000 IU/mL.\n4. Hepatitis B virus DNA \\<100 IU/mL.\n* Must have minimum age of 18 Years\n* Must have maximum age of 65 Years",
    "exclusionCriteria": "1. Patients with liver cirrhosis, Hepatocellular Carcinoma or AFP \\>2 ULN or other malignancies.\n2. Patients with other factors causing liver diseases.\n3. Pregnant and lactating women.\n4. Patients with concomitant HIV infection or congenital immune deficiency diseases.\n5. Patients with diabetes, autoimmune diseases.\n6. Patients with important organ dysfunctions.\n7. Patients with serious complications (e.g., infection, hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding.)\n8. Patients who receive antineoplastic or immunomodulatory therapy in the past 12 months.\n9. Patients with a previous use of IFN anti hepatitis B virus treatment or have NAs drug resistance.\n10. Patients who can't come back to clinic for follow-up on schedule."
}